My watch list  

34 Current news about the topic neuropathic pain


You can refine your search further. Select from the filter options on the left to narrow down your results.

New drug treatment reduces chronic pain


A new drug treatment has been found to be effective against chronic pain caused by nerve damage, also known as neuropathic pain, in patients who have had shingles. The researchers hope that the drug might also be effective against other causes of chronic neuropathic pain, such as diabetes, HIV, ...


A new role for sodium in the brain

Findings identify a novel pharmacological target for drug development


Researchers at McGill University have found that sodium – the main chemical component in table salt – is a unique “on/off” switch for a major neurotransmitter receptor in the brain. This receptor, known as the kainate receptor, is fundamental for normal brain function and is implicated in ...


Affectis Granted Patent for AFC-5128, other P2X7 Antagonists


Affectis Pharmaceuticals AG announced that the European Patent Office has granted a key patent for its oral brain-penetrant P2X7 antagonist AFC-5128 which is being developed for the treatment of neuropathic pain and multiple sclerosis.The European patent EP2105164 is related to the composition of ...


ExonHit Extends Strategic Collaboration with Allergan

Agreement to extend the collaboration until December 2013


ExonHit S.A. y announced the extension of its existing drug discovery collaboration with Allergan Sales, LLC. The collaboration was initiated in December 2002, and extended several times. It now is further extended until December 2013. The collaboration will continue to focus on the ...


Marijuana component could ease pain from chemotherapy drugs


A chemical component of the marijuana plant could prevent the onset of pain associated with drugs used in chemo therapy, particularly in breast cancer patients, according to researchers at Temple University's School of Pharmacy.The researchers published their findings, "Cannabidiol Prevents the ...


Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Postherpetic Neuralgia


Spinifex Pharmaceuticals, an Australian pain drug development company, announced the first patients have been treated in its Phase 2 clinical trial of EMA401 in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing ...


Evotec receives Milestone as Boehringer Ingelheim starts Phase I clinical trial in Pain


Evotec AG announced that a back-up compound in its strategic alliance with Boehringer Ingelheim has advanced into a Phase I clinical trial. Evotec will receive a milestone payment of EUR 2.0 million. The compound, which was discovered and optimised within the alliance, is being developed as a ...


Sun Pharma Announces USFDA Tentative Approval for Generic Cymbalta


Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta®, duloxetine hydrochloride delayed-release capsules. These generic duloxetine hydrochloride ...


Galapagos and University of Bristol enter drug discovery collaboration in chronic pain


Galapagos NV and the University of Bristol announced a new drug discovery collaboration aimed at developing treatments for chronic pain associated with diabetes (diabetic neuropathic pain). Galapagos' service division BioFocus will provide hit-to-lead and lead optimization services for a ...


Evotec Brings Project in Neuropathic Pain into Clinical Development in its Alliance with Boehringer Ingelheim

Evotec receives EUR 2.0 million milestone payment from Boehringer Ingelheim


Evotec AG announced that a compound in its strategic alliance with Boehringer Ingelheim has advanced into clinical trials. With the initiation of the Phase I clinical studies for this compound, Evotec will receive a milestone payment of EUR 2.0 million. The compound, which was discovered and ...


Page 1 From 4
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE